Dashboard
Manage Tickers

ABBV AbbVie Inc.

NYSE abbvie.com


$ 216.03 $ 3.59 (1.69 %)    

Tuesday, 04-Nov-2025 19:36:49 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 215.89
$ 212.37
$ 215.50 x 349
$ 217.08 x 57
$ 212.37 - $ 217.08
$ 158.28 - $ 243.06
6,184,010
na
381.56B
$ 0.46
$ 159.78
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-03-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-05-2023 03-31-2023 10-Q
12 02-17-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-18-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-02-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 02-19-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 02-21-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-16-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

citigroup-maintains-neutral-on-abbvie-lowers-price-target-to-235
Citigroup Maintains Neutral on AbbVie, Low...
11/03/2025 20:08:03

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $235.

what-the-options-market-tells-us-about-abbvie
What the Options Market Tells Us About AbbVie
11/03/2025 17:02:44

jp-morgan-maintains-overweight-on-abbvie-raises-price-target-to-260
JP Morgan Maintains Overweight on AbbVie, ...
11/03/2025 14:40:01

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $250 to $260.

looking-into-abbvie-incs-recent-short-interest
Looking Into AbbVie Inc's Recent Short Int...
10/31/2025 20:00:42

nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday
Nasdaq 100 Rebounds, Amazon Jumps 10% On S...
10/31/2025 17:26:36

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

abbvie-raises-2025-outlook-helped-by-strong-immunology-growth-boost-dividend
AbbVie Raises 2025 Outlook Helped By Stron...
10/31/2025 15:47:20

AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfol...

abbvie-executive-says-administrations-focus-on-achieving-greater-reductions-in-2027-medicare-drug-price-negotiation-round-was-clear-but-outcomes-will-not-impact-long-term-outlook
AbbVie Executive Says Administration's Foc...
10/31/2025 13:58:14

-Reuters

abbvie-raises-fy2025-adj-eps-guidance-from-1038-1058-to-1061-1065-vs-1053-est
AbbVie Raises FY2025 Adj EPS Guidance from...
10/31/2025 11:57:41

AbbVie (NYSE:ABBV) raises FY2025 Adj EPS guidance from $10.38-$10.58 to $10.61-$10.65 vs $10.53 analyst estimate..

abbvie-q3-adj-eps-186-beats-179-estimate-sales-15776b-beat-15590b-estimate
AbbVie Q3 Adj. EPS $1.86 Beats $1.79 Estim...
10/31/2025 11:56:32

AbbVie (NYSE:ABBV) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.79 by 4.09 pe...

abbvie-increases-quarterly-dividend-from-164-per-share-to-173-per-share-payable-on-february-17-2026-to-shareholders-of-record-january-16
AbbVie Increases Quarterly Dividend From $...
10/31/2025 11:55:18

earnings-scheduled-for-october-31-2025
Earnings Scheduled For October 31, 2025
10/31/2025 11:11:48

eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain
Eli Lilly Extends Lead In $150B Obesity Dr...
10/30/2025 20:04:44

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

abbvies-earnings-outlook
AbbVie's Earnings Outlook
10/30/2025 14:02:37

abbvie-says-canadas-drug-agency-recommends-elahere-be-reimbursed-with-conditions-for-treatment-of-certain-types-of-platinum-resistant-ovarian-cancers
AbbVie Says Canada's Drug Agency Recommend...
10/30/2025 11:31:44

ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC)ELAHERE® was submitted for reimbursement revie...

abbvie-says-in-two-replicate-phase-3-studies-rinvoq-achieved-co-primary-endpoints-of-50-reduction-in-total-vitiligo-area-scoring-index-from-baseline-and-75-in-facial-vitiligo-area-scoring-index
AbbVie Says In Two Replicate Phase 3 Studi...
10/29/2025 12:14:18

retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more
Retail Investors' Top Stocks With Earnings...
10/27/2025 14:38:22

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

live-on-cnbc-rob-sechan-announces-bought-more-abbvie
Live On CNBC, Rob Sechan Announces Bought ...
10/24/2025 16:30:49

qualcomm-aptiv-palo-alto-and-a-health-care-stock-on-cnbcs-final-trades
Qualcomm, Aptiv, Palo Alto And A Health Ca...
10/22/2025 12:17:16

Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Steph...

Core News & Articles
CNBC Halftime Report Final Trades: Palo Al...
10/21/2025 17:01:52

guggenheim-maintains-buy-on-abbvie-raises-price-target-to-242
Guggenheim Maintains Buy on AbbVie, Raises...
10/20/2025 12:34:56

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $227 to $242.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION